We show dose-escalating concentrations of a dominant TNFR2 antagonistic antibody killed TNFR2+ SS tumor cells and thus restored CD26− subpopulations of lymphocyte cell numbers to normal. This evidence concerns the gene DPP4 and neoplasm.